Safety and effectiveness of levosimendan in patients with predominant right heart failure

Herz

Volumn 33, Issue 5, 2008, Pages 368-373

  Poelzl, Gerhard ^a   Zwick, Ralph H ^a   Grander, Willhelm ^b   Metzler, Bernhard ^a   Jonetzko, Patrycja ^a   Frick, Mathias ^a   Ulmer, Hanno ^a   Pachinger, Otmar ^a   Roithinger, Franz X ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Congestive heart failure; Levosimendan; Low cardiac output; Right ventricular afterload; Right ventricular failure; Right ventricular stroke work

Indexed keywords

DIURETIC AGENT; DOPAMINE; LEVOSIMENDAN; NORADRENALIN;

ADULT; ARTICLE; CARDIOGENIC SHOCK; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; HEMODYNAMICS; HUMAN; LOADING DRUG DOSE; MALE; PULMONARY ARTERY OCCLUSION PRESSURE; RECURRENT DISEASE; SEPSIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STROKE; SUDDEN DEATH; SYSTEMIC VASCULAR RESISTANCE;

CARDIOTONIC AGENTS; FEMALE; HEART FAILURE; HUMANS; HYDRAZONES; MALE; MIDDLE AGED; PYRIDAZINES; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 51349149595     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-008-3051-2     Document Type: Article

References (16)

1. Mebazaa A, Karpati P, Renaud E, et al. Acute right ventricular failure - from pathophysiology to new treatments. Intensive Care Med 2003;30:185-96.
2. Jacobs AK, Leopold JA, Bates E, et al. Cardiogenic shock caused by right ventricular infarction: a report from the SHOCK registry. J Am Coll Cardiol 2003;41:1273-9.
3. Metha SR, Eikelboom JW, Natarajan MK, et al. Impact of right ventricular involvement on mortality and morbidity in patients with inferior myocardial infarction. J Am Coll Cardiol 2001;37:37-43.
4. Pfister M. Right ventricular involvement in myocardial infarction and cardiogenic shock. Lancet 2003;362:392-4.
5. Sibbald WJ, Driedger AA. Right ventricular function in acute disease states: pathophysiologic considerations. Crit Care Med 1993;11:339-45.
6. O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999;138:78-86.
7. Cleland JGF, McGowan J. Levosimendan: a new era for inodilator therapy for heart failure? Curr Opin Cardiol 2002;17:257-65.
8. Pollesello P, Ovaska M, Kaivola J, et al. Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem 1994;269:28584-90.
9. Yoloshiki H, Katsube Y, Sunagawa M, et al. Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamid-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol 1997;333:249-59.
10. Follath F, Cleland JFG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
11. Moiseyev VS, Poder P, Andrejevs N, et al. Randomized study on safety and effectiveness of levosimendan in patients with left ventricular heart failure after an acute myocardial infarction (the RUSSLAN study). Eur Heart J 2002;23:1422-32.
12. Grimm W. What is evidence-based, what is new in medical therapy of acute heart failure? Herz 2006;31:771-9.
13. Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000;102:2222-7.
14. Nieminen MS, Akkila J, Hasenfuss G, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1903-12.
15. Leather HA, Ver Eycken K, Segers P, et al. Effects of levosimendan on right ventricular function and ventriculovascular coupling in open chest pigs. Crit Care Med 2003;31:2339-43.
16. Lilleberg J, Nieminen MS, Akkila J, et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary bypass grafting. Eur Heart J 1998;19:660-8.